According to Lillys release, the trial met its primary endpoint: participants titrating up to the highest orforglipron dose lost 27.3 lb (12.4%) of body weight at 72 weeks versus about 0.9% weight loss with placebo
In long-term studies, patients taking Semaglutide GLP-1 lost an average of 15-20% of their initial body weight over periods of one to two years
The once-weekly injections also caused pain and bruises, and for a few days after injecting she experienced intense exhaustion, which made it difficult to get out of bed
Patients with type 2 diabetes or obesity may have additional risk factors for infections or other conditions that cause lymphadenopathy, making it essential to evaluate swollen lymph nodes thoroughly rather than automatically attributing them to GLP-1 therapy
He has found that a hybridtide with a kink near its end is able to wiggle between a helical and non-helical conformation within the receptor (both conformations being observed using cryo-electron microscopy)
Skip aspiration for subcutaneous shots it isnt needed and can add discomfort [13]